drugset / Trial / NCT04711226

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

NCT04711226

Phase 2 Withdrawn Anelixis Therapeutics, LLC
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

Timeline

Start
2021-02-19
Primary completion
2024-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegoprubart Monoclonal antibody Intravenous